While nearly 18% of U.S. adults have taken a GLP-1 drug for weight loss or to treat a chronic condition, about half of people will stop taking it within a year. Often, they don’t understand what is likely to come next. 🔗: https://t.co/wr42S7TXaD https://t.co/XfYXTkhEGG ...

While nearly 18% of U.S. adults have taken a GLP-1 drug for weight loss or to treat a chronic condition, about half of people will stop taking it within a year. Often, they don’t understand what is likely to come next. 🔗: https://t.co/C3wPtRUzir https://t.co/ZTIhNhuQRY ...

Of course, we were expecting approval for Lilly's product. We're proud to have pioneered this category, both with the injectable form being the first to introduce Wegovy injectable back in 2021 and then being the first to introduce an oral pill form version of whole GOBY. So we're excited about, you know, our benefits for consumers that are in search of medicine for weight loss.The Wegovy pill is highly efficacious. It is 17% weight loss observed with the pill, which is injectable type efficacy. Wegovy is t ...

The US Food and Drug Administration approved the second GLP-1 pill for weight loss, adding another option to a rapidly growing arsenal of obesity therapies. https://t.co/04WkvWfVyR https://t.co/cAUX4R3rn4 ...

The US Food and Drug Administration approved the second GLP-1 pill for weight loss, adding another option to a rapidly growing arsenal of obesity therapies. https://t.co/gCQ6ZRk2sM https://t.co/OVDAIligBj ...

Core Insights - The article discusses the rising interest in GLP-1 and weight loss stocks, highlighting the potential in the obesity market and the performance of key players like Eli Lilly, which became the first trillion-dollar pharmaceutical company last year [1] Industry Overview - The obesity market is recognized as a pandemic, with estimates suggesting over three billion people will be obese globally by 2030, including more than 100 million in the United States [2] - Currently, only about five million people in the U.S. are being served by existing treatments, indicating a significant unmet need in the market [2] Company Performance - **Viking Therapeutics Inc. (NASDAQ:VKTX)**: - Developing a weight loss drug VK-2735 targeting GLP-1 and GIP receptors - Shares are down 0.7% since Cramer's remarks, with a notable drop of 42% in August 2025 after mid-stage trial results showed only a 12% weight loss [6][7] - **Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)**: - Focuses on weight loss drugs that help retain lean muscle mass - Shares are up 10.6% since Cramer's remarks, with a year-to-date increase of 16.32% and a quarterly revenue of $3.75 billion, exceeding analyst expectations [8]

While nearly 18% of U.S. adults have taken a GLP-1 drug for weight loss or to treat a chronic condition, about half of people will stop taking it within a year. Often, they don’t understand what is likely to come next. 🔗: https://t.co/YFvzf3P8At https://t.co/6BlvQMMfJE ...

Identity is the way that that you can hack your own behavior so fast. It takes 30 seconds to understand it. If you were an Olympic athlete and you had a badass body, like you had a healthy diet, everything was in in perfect shape.You woke up every morning, you had great energy and all that stuff, and you wake up and you look in the mirror and this something weird happened overnight for some reason and you're 295 lbs. How fast would you get back to that body. You may set world records for for weight loss bec ...

While nearly 18% of U.S. adults have taken a GLP-1 drug for weight loss or to treat a chronic condition, about half of people will stop taking it within a year. Often, they don’t understand what is likely to come next. 🔗: https://t.co/YFvzf3P8At https://t.co/P9JmbTAE6b ...

India's cheap weight-loss drugs could reshape global obesity fight https://t.co/x3QWSHbEls ...